➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Harvard Business School
McKinsey
McKesson
AstraZeneca

Last Updated: June 19, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ETONOGESTREL

« Back to Dashboard

All Clinical Trials for etonogestrel

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00369967 Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents Terminated American College of Obstetricians and Gynecologists N/A 2007-02-01 We hypothesize that using "quick start" initiation of the contraceptive vaginal ring in adolescents seeking birth control will improve compliance compared to traditional start. We will conduct a randomized controlled trial comparing "quick start" to traditional start initiation of the contraceptive vaginal ring in adolescents seeking birth control. The primary study outcome is method continuation at 3, 6, and 12 months. Secondary outcomes include abnormal bleeding, product satisfaction, and adverse events.
NCT00369967 Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents Terminated Bayer N/A 2007-02-01 We hypothesize that using "quick start" initiation of the contraceptive vaginal ring in adolescents seeking birth control will improve compliance compared to traditional start. We will conduct a randomized controlled trial comparing "quick start" to traditional start initiation of the contraceptive vaginal ring in adolescents seeking birth control. The primary study outcome is method continuation at 3, 6, and 12 months. Secondary outcomes include abnormal bleeding, product satisfaction, and adverse events.
NCT00369967 Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents Terminated Virginia Commonwealth University N/A 2007-02-01 We hypothesize that using "quick start" initiation of the contraceptive vaginal ring in adolescents seeking birth control will improve compliance compared to traditional start. We will conduct a randomized controlled trial comparing "quick start" to traditional start initiation of the contraceptive vaginal ring in adolescents seeking birth control. The primary study outcome is method continuation at 3, 6, and 12 months. Secondary outcomes include abnormal bleeding, product satisfaction, and adverse events.
NCT00403793 Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057) Completed Bayer Phase 2 2003-10-01 Male volunteers receive a new hormonal contraceptive consisting of an implant releasing a hormone and hormone injections in order to investigate the suppressive effect on sperm production and reversibility of sperm production after end of treatment.
NCT00403793 Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057) Completed Merck Sharp & Dohme Corp. Phase 2 2003-10-01 Male volunteers receive a new hormonal contraceptive consisting of an implant releasing a hormone and hormone injections in order to investigate the suppressive effect on sperm production and reversibility of sperm production after end of treatment.
NCT00612508 Hormonal Contraception and Vaginal Health Completed Oregon Clinical and Translational Research Institute N/A 2007-05-01 The purpose of this study is to help determine if the route by which women receive hormonal contraception causes different changes to occur in the lining of the vagina. The investigators plan to compare an oral route (taking birth control pills) with a vaginal route (using a vaginal ring).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for etonogestrel

Condition Name

Condition Name for etonogestrel
Intervention Trials
Contraception 28
HIV 5
Breakthrough Bleeding 3
Bleeding 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for etonogestrel
Intervention Trials
Hemorrhage 9
Uterine Hemorrhage 6
Dysmenorrhea 3
Metrorrhagia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for etonogestrel

Trials by Country

Trials by Country for etonogestrel
Location Trials
United States 27
Brazil 7
Uganda 3
Egypt 2
Kenya 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for etonogestrel
Location Trials
Colorado 4
Oregon 4
Virginia 3
Georgia 2
Missouri 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for etonogestrel

Clinical Trial Phase

Clinical Trial Phase for etonogestrel
Clinical Trial Phase Trials
Phase 4 25
Phase 3 9
Phase 2/Phase 3 2
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for etonogestrel
Clinical Trial Phase Trials
Completed 19
Not yet recruiting 17
Recruiting 10
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for etonogestrel

Sponsor Name

Sponsor Name for etonogestrel
Sponsor Trials
Merck Sharp & Dohme Corp. 20
University of Colorado, Denver 6
University of Pittsburgh 6
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for etonogestrel
Sponsor Trials
Other 67
Industry 25
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
McKesson
Dow
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.